Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Krishnamoorthy

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Molecular Cancer Research : MCR|July 21, 2023
Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric EffectsIñigo Landa, Caitlin E M Thornton, Bin Xu, et al.
Cancer Research|May 16, 2018
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid CancersBrian R Untch, Vanessa Dos Anjos, Maria E R Garcia-Rendueles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2023
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine TherapyLaura Boucai, Mahesh Saqcena, Fengshen Kuo, et al.
The Journal of Clinical Investigation|February 16, 2016
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancersIñigo Landa, Tihana Ibrahimpasic, Laura Boucai, et al.
Cancer Discovery|October 12, 2018
<i>EIF1AX</i> and <i>RAS</i> Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYCGnana P Krishnamoorthy, Natalie R Davidson, Steven D Leach, et al.
Endocrine-Related Cancer|April 23, 2021
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancersKathleen A Luckett, Jennifer R Cracchiolo, Gnana P Krishnamoorthy, et al.
Biorxiv : the Preprint Server for Biology|March 17, 2025
Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitorsVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
The Journal of Clinical Investigation|August 19, 2025
Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancersVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
Scientific Data|December 29, 2024
Comprehensive Mass Spectral Libraries of Human Thyroid Tissues and CellsLu Li, Wenhao Jiang, Wenjun Wei, et al.
Cancer Discovery|December 15, 2020
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation TherapiesMahesh Saqcena, Luis Javier Leandro-Garcia, Jesper L V Maag, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Molecular Cancer Research : MCR|July 21, 2023
Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric EffectsIñigo Landa, Caitlin E M Thornton, Bin Xu, et al.
Cancer Research|May 16, 2018
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid CancersBrian R Untch, Vanessa Dos Anjos, Maria E R Garcia-Rendueles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2023
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine TherapyLaura Boucai, Mahesh Saqcena, Fengshen Kuo, et al.
The Journal of Clinical Investigation|February 16, 2016
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancersIñigo Landa, Tihana Ibrahimpasic, Laura Boucai, et al.
Cancer Discovery|October 12, 2018
<i>EIF1AX</i> and <i>RAS</i> Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYCGnana P Krishnamoorthy, Natalie R Davidson, Steven D Leach, et al.
Endocrine-Related Cancer|April 23, 2021
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancersKathleen A Luckett, Jennifer R Cracchiolo, Gnana P Krishnamoorthy, et al.
Biorxiv : the Preprint Server for Biology|March 17, 2025
Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitorsVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
The Journal of Clinical Investigation|August 19, 2025
Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancersVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
Scientific Data|December 29, 2024
Comprehensive Mass Spectral Libraries of Human Thyroid Tissues and CellsLu Li, Wenhao Jiang, Wenjun Wei, et al.
Cancer Discovery|December 15, 2020
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation TherapiesMahesh Saqcena, Luis Javier Leandro-Garcia, Jesper L V Maag, et al.
Pageof 7